Indiva Balance Sheet Health

Financial Health criteria checks 2/6

Indiva tiene unos fondos propios totales de CA$371.1K y una deuda total de CA$21.4M, lo que sitúa su ratio deuda/fondos propios en 5776.7%. Sus activos y pasivos totales son CA$38.1M y CA$37.7M respectivamente.

Key information

5,776.7%

Debt to equity ratio

CA$21.44m

Debt

Interest coverage ratio	n/a
Cash	CA$3.91m
Equity	CA$371.13k
Total liabilities	CA$37.72m
Total assets	CA$38.09m

Recent financial health updates

Recent updates

Indiva Limited (CVE:NDVA) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Sep 29

Is Indiva (CVE:NDVA) Using Debt In A Risky Way?

Sep 17

Is Indiva (CVE:NDVA) A Risky Investment?

Apr 19

Is Indiva (CVE:NDVA) Using Too Much Debt?

Feb 26

Would Indiva (CVE:NDVA) Be Better Off With Less Debt?

Sep 04

Would Indiva (CVE:NDVA) Be Better Off With Less Debt?

Nov 30

Financial Position Analysis

Pasivos a corto plazo: NDVALos activos a corto plazo (CA$13.1M) no cubren sus pasivos a corto plazo (CA$15.3M).

Pasivo a largo plazo: Los activos a corto plazo de NDVA (CA$13.1M) no cubren sus pasivos a largo plazo (CA$22.4M).

Debt to Equity History and Analysis

Nivel de deuda: La relación deuda neta-capital de NDVA (4721.8%) se considera alta.

Reducción de la deuda: NDVAha pasado de 13.3% a 5776.7% en los últimos 5 años.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Cash runway estable: Aunque no es rentable NDVA tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de free cash flow.

Pronóstico de cash runway: NDVA no es rentable pero tiene suficiente liquidez para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 11.6% al año.

Discover healthy companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Indiva Balance Sheet Health

Financial Health criteria checks 2/6

Key information

Recent financial health updates

Is Indiva (CVE:NDVA) Using Debt In A Risky Way?

Is Indiva (CVE:NDVA) A Risky Investment?

Is Indiva (CVE:NDVA) Using Too Much Debt?

Would Indiva (CVE:NDVA) Be Better Off With Less Debt?

Would Indiva (CVE:NDVA) Be Better Off With Less Debt?

Recent updates

New major risk - Market cap size

Insufficient new directors

Indiva Limited announced that it expects to receive CAD 4.312 million in funding

Indiva Limited announced that it expects to receive CAD 4 million in funding

Price target increased by 15% to CA$0.15

Indiva Limited Provides Revenue Guidance for Fourth Quarter of 2023

Third quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.018 loss in 3Q 2022)

Indiva Limited to Report Q3, 2023 Results on Nov 21, 2023

Indiva Limited (CVE:NDVA) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Is Indiva (CVE:NDVA) Using Debt In A Risky Way?

Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.017 loss in 2Q 2022)

Indiva Limited to Report Q2, 2023 Results on Aug 29, 2023

Indiva Limited Launches No Future Gummies and Vapes

New minor risk - Shareholder dilution

New major risk - Share price stability

Indiva Limited announced that it expects to receive CAD 2.155617 million in funding from Canopy Growth Corporation

Indiva Limited Provides Revenue Guidance for the Second Quarter of 2023

Indiva Limited, Annual General Meeting, Jul 18, 2023

Indiva Limited to Report Q1, 2023 Results on May 16, 2023

Is Indiva (CVE:NDVA) A Risky Investment?

Full year 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CA$0.50

Indiva Limited to Report Q3, 2022 Results on Nov 22, 2022

Indiva Limited Provides Revenue Guidance for the Second Half and Full Year of 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Indiva Limited to Report Q2, 2022 Results on Aug 16, 2022

Indiva Limited Provides Revenue Guidance for the Second Quarter of 2022

Consensus estimates of losses per share improve by 62%

Indiva Limited Provides Revenue Guidance for the Second Quarter of 2022

Indiva Limited to Report Q1, 2022 Results on May 19, 2022

Price target decreased to CA$0.60

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Indiva Limited Provides Net Revenue Guidance for the First Quarter of 2022

Indiva Limited, Annual General Meeting, Jun 23, 2022

Indiva Limited to Report Fiscal Year 2021 Results on Apr 26, 2022

Is Indiva (CVE:NDVA) Using Too Much Debt?

Indiva Limited Launches New Cannabis Edible Designed for MicroDosing

Indiva Launches New Cannabis Edible Formulated for Night-Time Use

Third quarter 2021 earnings released: CA$0.047 loss per share (vs CA$0.035 loss in 3Q 2020)

Would Indiva (CVE:NDVA) Be Better Off With Less Debt?

Second quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.029 loss in 2Q 2020)

Indiva Limited Provides Revenue Guidance for the Second Half of 2021

First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.029 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.16 loss per share (vs CA$0.14 loss in FY 2019)

Indiva Limited to Introduce Two New Bhang Chocolate Flavours Nationally in Second Quarter of 2021

Indiva Limited Ships Wana Quick Gummies

Indiva Limited Appoints Russell Wilson to the Board of Directors

Indiva Limited announced that it has received CAD 11 million in funding from Sundial Growers Inc.

Indiva Announces Extension to License Agreement with Wana Brands Inc

Indiva Limited announced that it expects to receive CAD 11 million in funding from Sundial Growers Inc.

New 90-day high: CA$0.49

New 90-day high: CA$0.28

Independent Director recently bought CA$65k worth of stock

Indiva Limited Promotes Rob Carse to Chief Operating Officer

Price target raised to CA$0.63

Analysts increase revenue estimates to CA$14.9m

Would Indiva (CVE:NDVA) Be Better Off With Less Debt?

Third quarter 2020 earnings released: CA$0.035 loss per share

New 90-day low: CA$0.21

New 90-day low: CA$0.23

Indiva Secures Agreement with Medical Cannabis by Shoppers Inc

Indiva Ships Wana Sour Gummies to Alberta, Saskatchewan, and Yukon Territory

Indiva Ships Wana™ Sour Gummies to British Columbia

Analysts update estimates

Price target lowered to CA$0.55

First half earnings released

Indiva Limited announced that it has received CAD 5.179499 million in funding from Marotta Investments Limited, Prairie Merchant Corporation, ATB Capital Markets Inc.

New 90-day low - CA$0.27

Financial Position Analysis